107 related articles for article (PubMed ID: 2858709)
41. Six-year results of a controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer.
Wilson AJ; Baum M; Brinkley DM; Dossett JA; McPherson K; Patterson JS; Rubens RD; Smiddy FG; Stoll BA; Richards D
World J Surg; 1985 Oct; 9(5):756-64. PubMed ID: 3904233
[No Abstract] [Full Text] [Related]
42. Tamoxifen (Nolvadex) for premenopausal patients with advanced breast cancer.
Margreiter R; Wiegele J
Breast Cancer Res Treat; 1984; 4(1):45-8. PubMed ID: 6365211
[TBL] [Abstract][Full Text] [Related]
43. Adjuvant tamoxifen for male breast cancer (MBC).
Ribeiro G; Swindell R
Br J Cancer; 1992 Feb; 65(2):252-4. PubMed ID: 1739625
[TBL] [Abstract][Full Text] [Related]
44. Review of mortality results in randomised trials in early breast cancer.
Lancet; 1984 Nov; 2(8413):1205. PubMed ID: 6150246
[No Abstract] [Full Text] [Related]
45. The steady-state pharmacokinetics of tamoxifen and its metabolites in breast cancer patients.
Soininen K; Kleimola T; Elomaa I; Salmo M; Rissanen P
J Int Med Res; 1986; 14(3):162-5. PubMed ID: 3522312
[TBL] [Abstract][Full Text] [Related]
46. Adjuvant hormonal chemotherapy in early breast cancer: early results from a controlled trial.
Senanayake F
Lancet; 1984 Nov; 2(8412):1148-9. PubMed ID: 6150196
[No Abstract] [Full Text] [Related]
47. Adjuvant tamoxifen in postmenopausal patients with breast cancer and negative axillary lymph nodes.
Scholten C; Sevelda P; Kurz C; Salzer H; Kubista E; Staffen A; Czerwenka K; Spona J; Aiginger P; Zielinski CC
Eur J Cancer; 1992; 28A(12):2083. PubMed ID: 1419306
[No Abstract] [Full Text] [Related]
48. Poor response of breast cancer to tamoxifen.
McDonald PJ; Carpenter R; Royle GT; Taylor I
Postgrad Med J; 1990 Dec; 66(782):1029-31. PubMed ID: 2084647
[TBL] [Abstract][Full Text] [Related]
49. Dosage and duration of tamoxifen treatment for mastalgia: a controlled trial.
Fentiman IS; Caleffi M; Hamed H; Chaudary MA
Br J Surg; 1988 Sep; 75(9):845-6. PubMed ID: 3052691
[TBL] [Abstract][Full Text] [Related]
50. The effects of the administration of tamoxifen, ethynyloestradiol, and prednisolone on the activities of certain enzymes of carbohydrate metabolism in primary human breast carcinomas in vivo.
Deshpande N; Mitchell I; Maltinti M; Boi A; Di Martino L
Br J Cancer; 1985 Aug; 52(2):241-4. PubMed ID: 3161533
[TBL] [Abstract][Full Text] [Related]
51. A multicentre trial to compare a loading dose regimen of tamoxifen ('Nolvadex') with conventional dosing in the treatment of advanced breast cancer. The British Tamoxifen Study Group.
Spooner D; Fairlamb D; Fermont D
Clin Oncol (R Coll Radiol); 1991 May; 3(3):133-6. PubMed ID: 2069877
[TBL] [Abstract][Full Text] [Related]
52. Myelosuppression occurring after receiving tamoxifen for breast cancer. International Adjuvant Therapy Organisation.
Br J Radiol; 1985 Dec; 58(696):1220. PubMed ID: 3842636
[No Abstract] [Full Text] [Related]
53. The effect of tamoxifen and medroxyprogesterone on giant cell formation by monocytes from patients with breast cancer.
Al-Sumidaie AM
J Cancer Res Clin Oncol; 1988; 114(4):399-404. PubMed ID: 3410879
[TBL] [Abstract][Full Text] [Related]
54. The right to a fair trial.
Dixon B
Curr Biol; 1998 May; 8(10):R328. PubMed ID: 9601628
[No Abstract] [Full Text] [Related]
55. NSABP halts B-14 trial: no benefit seen beyond 5 years of tamoxifen use.
J Natl Cancer Inst; 1995 Dec; 87(24):1829. PubMed ID: 7494223
[No Abstract] [Full Text] [Related]
56. Clinical trial of tamoxifen in patients with irresectable pancreatic carcinoma.
Morris DL
Br J Surg; 1993 Aug; 80(8):1083. PubMed ID: 8402083
[No Abstract] [Full Text] [Related]
57. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation.
Lancet; 1983 Feb; 1(8319):257-61. PubMed ID: 6130291
[TBL] [Abstract][Full Text] [Related]
58. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh.
Lancet; 1987 Jul; 2(8552):171-5. PubMed ID: 2885637
[TBL] [Abstract][Full Text] [Related]
59. 50th anniversary of the first clinical trial with ICI 46,474 (tamoxifen): then what happened?
Jordan VC
Endocr Relat Cancer; 2021 Jan; 28(1):R11-R30. PubMed ID: 33151906
[TBL] [Abstract][Full Text] [Related]
60. Incorporating competing risk theory into evaluations of changes in cancer survival: making the most of cause of death and routinely linked sociodemographic data.
Wright CM; Nowak AK; Halkett G; Moorin RE
BMC Public Health; 2020 Jun; 20(1):1002. PubMed ID: 32586298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
